Author + information
- Received February 10, 1995
- Revision received June 12, 1995
- Accepted August 10, 1995
- Published online January 1, 1996.
- Francisco Fernández-Avilés, MD, PhD, FACC**,
- Joaquín Jesús Alonso, MD, PhD,
- Juan Manuel Durán, MD,
- Federico Gimeno, MD, PhD,
- Juan Carlos Muñoz, MD,
- Luis de la Fuente, MD and
- José Alberto San Román, MD, PhD
- ↵**Address for correspondence: Dr. Francisco Fernández-Avilés, Departamento de Cardiología, Hospital Universitario, Ramón y Cajal 3, Valladolid 47011, Spain.
Objectives. This study was designed to evaluate the effect of an antithrombotic regimen without full early anticoagulation on subacute occlusion, bleeding, hospital stay and restenosis after elective coronary stenting.
Background. Subacute occlusion is a major limitation of stenting. Aggressive antithrombotic therapy is not fully prophylactic against this complication, carries risk of bleeding, prolongs hospital stay and reduces cost-effectiveness.
Methods. We studied 110 consecutive patients (121 lesions) who underwent elective Palmaz-Schatz stenting. Intravenous heparin was given only during the procedure. After stenting, patients took aspirin, dipyridamole, dextran, warfarin and low molecular weight heparin (enoxaparin, 40 mg subcutaneously daily, stopped when an international normalized ratio of 2 to 3 was achieved). The first 52 patients (group A) underwent coronary angiography 24 h after stenting, and hospital stay was extended until an international normalized ratio of 2 to 3.5 was achieved. The remaining 58 patients (group B) were discharged 24 h after stenting. Clinical and angiographic follow-up were performed 1 and 6 months after stenting for all patients.
Results. In group A the activated partial thromboplastin time remained normal (30 ± 6.2 s [mean ±SD]) during enoxaparin administration, and hospital stay was 9.1 ± 4.3 days. In group B hospital stay was 27 ± 8 h. No major cardiac events occurred within the first month in patients from both groups. At 1 and 30 days all stented lesions remained patent. Only two patients (1.8%, 95% confidence interval [CI] 0.32% to 7%) developed bleeding. At 6 months, the restenosis rate was 22% (95% CI 15% to 30%).
Conclusions. After coronary stenting with optimal angiographic results, this new antithrombotic regimen prevented subacute stent occlusion and bleeding, with a brief hospital stay. No detrimental effect on the previously reported restenosis rate was observed.
- Received February 10, 1995.
- Revision received June 12, 1995.
- Accepted August 10, 1995.
- American College of Cardiology